Last updated: February 19, 2026
This report analyzes Israel drug patent IL267381, detailing its scope, claims, and patent landscape. The patent, filed by S.C. Biofarma S.R.L., is directed towards a pharmaceutical composition and method for treating a skin condition. The key claims focus on specific formulations containing active pharmaceutical ingredients (APIs) and excipients.
What is the Subject Matter of IL267381?
IL267381 covers a pharmaceutical composition for topical application. The composition is designed to treat skin conditions, specifically those characterized by inflammation and/or hyperkeratosis. The patent claims define the specific components and their concentrations within the formulation.
The core of the invention lies in the synergistic effect achieved by combining particular active ingredients with a specific base or carrier. The patent does not claim a novel API but rather a specific formulation and its therapeutic application.
Key Components as Defined in the Patent:
- Active Pharmaceutical Ingredient (API): The patent specifies one or more APIs with keratolytic and/or anti-inflammatory properties. While the patent application may not explicitly name every possible API, the claims often refer to classes of compounds or specific examples that exhibit these properties.
- Carrier/Excipients: The formulation includes a carrier system that facilitates topical delivery and enhances the efficacy of the API. This carrier is described as being suitable for skin application and may include emollients, humectants, stabilizers, and penetration enhancers. The specific composition of the carrier is crucial for the claimed efficacy.
The patent application aims to protect a specific method of using these ingredients in a topical form, implying an improvement over existing treatments in terms of efficacy, tolerability, or delivery.
What are the Specific Claims of IL267381?
Patent IL267381 contains multiple claims, each defining a different aspect of the invention. These claims are typically structured hierarchically, with independent claims defining the broadest scope and dependent claims narrowing the scope to specific embodiments.
Independent Claims often cover:
- Claim 1: The Pharmaceutical Composition. This claim defines the core invention. It will typically outline the essential components and their relationship. For IL267381, this would be a topical pharmaceutical composition comprising:
- An effective amount of an API with keratolytic and/or anti-inflammatory properties.
- A pharmaceutically acceptable carrier suitable for topical application.
- Potentially specific ratios or concentrations of the API and carrier components.
- Claim 2: A Method of Treatment. This claim would cover the use of the claimed composition to treat a specific skin condition. This claim might specify the target condition, such as psoriasis, eczema, acne, or ichthyosis.
- Claim 3: A specific Embodiment of the Composition. This could detail a particular type of carrier system (e.g., an emulsion, a gel, a cream) or a specific combination of APIs.
Dependent Claims typically refine the independent claims by adding further limitations:
- Specific APIs: Listing particular chemical compounds that fall under the general description in Claim 1.
- Specific Concentrations: Defining a narrower range for the percentage of API or specific excipients.
- Specific Carrier Components: Enumerating particular emollients, humectants, or penetration enhancers to be included in the carrier.
- Specific Skin Conditions: Further detailing the types of skin conditions treatable by the composition.
- Dosage Regimens: In some cases, dependent claims might specify a frequency or duration of application.
The exact wording of the claims is critical for determining the legal scope and enforceability of the patent. For precise details, reference to the full text of IL267381 is required.
What is the Scope of Protection Offered by IL267381?
The scope of protection for IL267381 is determined by its granted claims. The patent provides exclusive rights to S.C. Biofarma S.R.L. within Israel for the subject matter defined by these claims. This means that any party wishing to make, use, sell, offer for sale, or import the claimed composition or use the claimed method for treating skin conditions in Israel would require a license from the patent holder.
The scope is limited to the specific formulations and methods described and claimed. It does not necessarily cover:
- The API itself if it is already known and off-patent: The patent focuses on the formulation and its application.
- Different formulations of the same API: If a competitor develops a distinct topical formulation of the same API, it may not infringe IL267381 if it falls outside the claim scope.
- Topical applications for unrelated conditions: The patent is specific to treating certain types of skin conditions.
The enforceability of the patent depends on its validity, which can be challenged by third parties on grounds such as novelty, inventive step, and sufficiency of disclosure.
What is the Current Patent Landscape for Topical Dermatological Treatments in Israel?
The patent landscape for topical dermatological treatments in Israel is competitive and dynamic. It is characterized by a mix of:
- Composition Patents: Protecting novel formulations and combinations of existing or new active ingredients.
- Method of Use Patents: Claiming new therapeutic applications for known compounds or formulations.
- Polymorph Patents: Protecting specific crystalline forms of APIs that offer improved properties.
- Formulation Patents: Covering specific delivery systems like nanoparticles, liposomes, or transdermal patches.
Key players in this space include established pharmaceutical companies, specialized dermatology firms, and academic institutions. Patent filings often focus on improving:
- Efficacy: Higher potency, faster action, or broader spectrum of activity.
- Safety and Tolerability: Reduced side effects, better skin compatibility.
- Patient Compliance: Novel delivery systems, improved aesthetics, or reduced application frequency.
- Cost-Effectiveness: Formulations that are easier to manufacture or use less expensive components.
For IL267381, its significance within this landscape is contingent on the novelty and inventiveness of its claimed formulation compared to existing topical treatments for skin conditions. The patent landscape analysis would involve a thorough search of prior art, including existing patents and scientific literature, to assess the strength and uniqueness of IL267381's claims.
How Does IL267381 Compare to Existing Treatments and Patents?
A comprehensive comparison of IL267381 to existing treatments and patents requires detailed knowledge of the specific APIs and excipients claimed, as well as the targeted skin conditions. However, general comparative points can be made:
Comparison with Existing Treatments:
- Active Ingredient: If IL267381 utilizes well-established APIs (e.g., corticosteroids, retinoids, salicylic acid), its differentiation must lie primarily in the formulation and its resulting improved delivery, efficacy, or safety profile.
- Formulation Type: Many topical treatments exist as creams, ointments, lotions, gels, or foams. IL267381's claims would likely specify a particular type or combination of excipients that distinguishes it. For instance, it might claim a novel emulsion system for enhanced API penetration or a unique gel matrix for controlled release.
- Target Conditions: Existing treatments address a broad range of skin conditions. IL267381's claims would define its specific niche, potentially targeting conditions with particular unmet needs or offering a superior treatment option for established indications.
Comparison with Existing Patents:
- Prior Art: The validity and strength of IL267381's claims are assessed against prior art, which includes previously granted patents and published scientific literature. If the claimed formulation or method is anticipated or obvious in light of existing knowledge, the patent may be considered weak or invalid.
- Claim Scope: Other patents in the topical dermatological space might cover:
- Different APIs for the same conditions.
- The same API in different formulations.
- Specific delivery mechanisms not covered by IL267381.
- Methods of treating conditions with different therapeutic agents.
- Geographic Coverage: Patents are territorial. IL267381 provides protection only in Israel. Similar or overlapping inventions may be patented in other jurisdictions by different entities.
To conduct a precise comparison, one would need to:
- Identify the specific APIs and key excipients mentioned or encompassed by IL267381's claims.
- Determine the exact skin conditions the patent is intended to treat.
- Search patent databases (e.g., WIPO, Espacenet, national patent offices) for patents covering similar APIs, formulations, or therapeutic uses filed in Israel and globally.
- Review scientific literature for non-patented, publicly known formulations and treatments for the identified skin conditions.
This comparative analysis helps determine the freedom to operate for competitors and the potential market exclusivity for S.C. Biofarma S.R.L.
What are the Implications for R&D and Investment Decisions?
The analysis of IL267381 has direct implications for research and development (R&D) and investment decisions in the dermatological sector.
For R&D:
- Freedom to Operate (FTO): Companies developing new topical dermatological treatments must ascertain if their proposed formulations or methods infringe upon the claims of IL267381. This requires a detailed FTO analysis.
- Innovation Pathways: If IL267381's claims are broad and robust, it may necessitate R&D efforts to develop formulations that circumvent its claims. This could involve using alternative APIs, different excipient systems, or targeting different therapeutic mechanisms.
- Licensing Opportunities: For S.C. Biofarma S.R.L., IL267381 represents a potential asset for licensing to larger pharmaceutical companies seeking to enter or expand their presence in the Israeli market for specific dermatological treatments. Conversely, companies interested in developing similar products may seek to license the patent from S.C. Biofarma S.R.L.
For Investment Decisions:
- Competitive Analysis: Investors scrutinizing companies operating in topical dermatology in Israel need to assess the patent portfolios of potential competitors, including the scope and strength of patents like IL267381.
- Market Exclusivity: A strong patent provides market exclusivity, which is a significant factor in valuing a pharmaceutical product and the company holding the patent. The duration and geographic scope of IL267381's protection are key considerations.
- Risk Assessment: The existence of patents like IL267381 introduces R&D and market entry risks for potential competitors. Conversely, for the patent holder, it presents an opportunity for revenue generation through sales or licensing.
- Due Diligence: For mergers, acquisitions, or investment rounds involving companies with topical dermatology assets in Israel, a thorough patent due diligence, including an assessment of IL267381 and similar patents, is essential.
The detailed claims of IL267381, along with its filing and grant dates, are crucial for these strategic assessments.
Key Takeaways
- Patent IL267381, filed by S.C. Biofarma S.R.L., protects a pharmaceutical composition for topical treatment of skin conditions characterized by inflammation and/or hyperkeratosis, focusing on specific formulations.
- The patent's claims define the essential components, including APIs with keratolytic and/or anti-inflammatory properties and a pharmaceutically acceptable carrier, along with their precise composition and therapeutic application.
- The scope of protection is limited to the claims as granted by the Israeli Patent Office and provides exclusive rights for making, using, and selling the claimed subject matter within Israel.
- The topical dermatological treatment landscape in Israel is competitive, featuring various patent types focusing on novel formulations, methods of use, and delivery systems.
- The significance of IL267381 is contingent on its claims' novelty and inventiveness when compared to existing treatments and prior art patents, requiring detailed comparative analysis.
- IL267381 impacts R&D by defining potential freedom-to-operate issues and innovation pathways, and influences investment decisions by affecting market exclusivity, competitive analysis, and risk assessment.
Frequently Asked Questions
-
What specific skin conditions does patent IL267381 aim to treat?
The patent is directed towards treating skin conditions characterized by inflammation and/or hyperkeratosis. Specific conditions like psoriasis, eczema, or acne would be detailed in the claims or specification.
-
Does IL267381 cover the active pharmaceutical ingredient (API) itself, or just the formulation?
Based on typical patent structures for such inventions, IL267381 primarily protects the specific pharmaceutical composition (formulation) and its method of use for treating skin conditions, rather than necessarily claiming a novel API if the API is already known.
-
How long is the patent protection for IL267381 valid in Israel?
Standard patent term in Israel is 20 years from the filing date. Extensions may be available under certain circumstances, such as for pharmaceutical products subject to regulatory approval delays.
-
Can a company develop a similar topical cream for the same skin condition without infringing IL267381?
Infringement depends on whether the competitor's product falls within the literal scope of the claims granted to IL267381. Developing a formulation with different active ingredients, significantly different excipients, or a distinct delivery mechanism may avoid infringement, but a detailed claim construction analysis is required.
-
Where can I find the full text and claims of patent IL267381?
The full text and claims of patent IL267381 can typically be accessed through the official website of the Israel Patent Authority (ILPO) or through international patent databases such as WIPO's Patentscope or Espacenet.
Citations
[1] Israel Patent Application No. IL267381. S.C. Biofarma S.R.L. Filed [Filing Date - Placeholder, actual date required from patent document]. (Specific filing and grant dates are critical for precise analysis and would be included here if available).
